Parkinson's Disease

Hippocampal volume changes in Parkinson’s disease 2:05
Hippocampal volume changes in Parkinson’s disease
Ivan Rektor • 17 Mar 2022
Investigating α-synuclein aggregation as a therapeutic target in Parkinson’s disease 1:21
Investigating α-synuclein aggregation as a therapeutic target in Parkinson’s disease
Tim Bartels • 17 Mar 2022
Treating central autonomic disorders 1:52
Treating central autonomic disorders
Elizabeth Coon • 1 Apr 2022
In vivo interactions between Nedd4 ubiquitin ligases and α-synuclein in Parkinson’s disease models 3:52
In vivo interactions between Nedd4 ubiquitin ligases and α-synuclein in Parkinson’s disease models
James Conway • 11 Mar 2022
An update on biomarkers for use in Parkinson’s Disease 1:40
An update on biomarkers for use in Parkinson’s Disease
Fabrizio Stocchi • 18 Mar 2022
New drugs for treatment of Parkinson’s disease 1:47
New drugs for treatment of Parkinson’s disease
Fabrizio Stocchi • 18 Mar 2022
How can the gut microbiome modulate the peripheral and brain immune systems? 4:45
How can the gut microbiome modulate the peripheral and brain immune systems?
Giulio Pasinetti • 18 Mar 2022
Is α-synuclein aggregation a cause or consequence of Parkinson’s disease? 1:34
Is α-synuclein aggregation a cause or consequence of Parkinson’s disease?
Tiago Outeiro • 18 Mar 2022
How does α-synuclein propagate from cell to cell? 1:37
How does α-synuclein propagate from cell to cell?
Tiago Outeiro • 18 Mar 2022
α-synuclein conformation as a novel blood biomarker in Parkinson’s disease 3:07
α-synuclein conformation as a novel blood biomarker in Parkinson’s disease
Tim Bartels • 17 Mar 2022
Targeting α-synuclein as a therapy for Parkinson’s disease: strategies in the pipeline 1:54
Targeting α-synuclein as a therapy for Parkinson’s disease: strategies in the pipeline
Tiago Outeiro • 18 Mar 2022
Sleep as a biomarker for neurodegenerative disorders 1:02
Sleep as a biomarker for neurodegenerative disorders
Emmanuel Mignot • 14 Mar 2022
Potential targets for Parkinson’s disease treatment 1:09
Potential targets for Parkinson’s disease treatment
Fabrizio Stocchi • 18 Mar 2022
Latest developments in symptomatic treatment of Parkinson’s disease 1:47
Latest developments in symptomatic treatment of Parkinson’s disease
Fabrizio Stocchi • 18 Mar 2022
Aberrant synuclein-lipid binding in Lewy body formation 2:09
Aberrant synuclein-lipid binding in Lewy body formation
Tim Bartels • 17 Mar 2022
Impact of α-synuclein on synaptic function 1:17
Impact of α-synuclein on synaptic function
Tiago Outeiro • 18 Mar 2022
The content of VJNeurology is intended for healthcare professionals